TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04909775
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000mg/m2, Day 1 and Day 8 of 3-week, for 4 cycles
Study: NCT06127381
Drug: Glycolic acid tetrasubstituted piceatannol (TGKP)
DrugBank: Glycolic acid (DB03085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A total of 25 volunteers will be randomized and receive the study drug, of which 5 - will receive ¼ therapeutic dose, 5 - will receive ½ therapeutic dose, 15 - will receive the full therapeutic dose.
Study: NCT05594121
Drug: Extended Release Subcutaneous Buprenorphine
Normalized name: Buprenorphine Extended-Release Injection
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly subcutaneous injections of long-acting buprenorphine
Study: NCT05594121
Drug: Immediate Release Sublingual Buprenorphine
Normalized name: buprenorphine Sublingual Tablet
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Daily sublingual fast-acting buprenorphine
Study: NCT00754949
Drug: 0.1% Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.
Study: NCT04640493
Drug: Dapagliflozin
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: If patients have been diagnosed with SDB using the WatchPat device, they will start dapagliflozin. Repeat WatchPat SDB assessment will be performed after 3 and 6 months of continuous dapagliflozin therapy.
Study: NCT04173260
Drug: Deutetrabenazine 6 MG
Normalized name: deutetrabenazine 6 MG
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Increasing doses of Deutetrabenazine
Study: NCT05014464
Drug: Crizotinib
Normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Crizotinib 250mg po bid Aectinib 600mg po bid Lorlatinib 100mg po qd Brigatinib, 90mg po qd for one week and than 180mg po qd forever Pemetrexed 500mg/m2
Study: NCT04603495
Drug: Pelabresib
Normalized name: Pelabresib
DrugBank: Pelabresib anhydrous (DB17129)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-blind treatment (pelabresib or matching placebo) will be administered daily for 14 consecutive days followed by a 7-day break, which is considered 1 cycle of treatment (1 cycle = 21 days).~Pelabresib is a small molecule inhibitor of BET proteins with a novel mechanism of action and potential for disease-modifying effects in MF.
Study: NCT04603495
Drug: Ruxolitinib
Normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ruxolitinib is a JAK inhibitor and a current, approved treatment option for MF.
Study: NCT06090539
Drug: BMS-986458
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Specified dose on specified days.
Study: NCT06090539
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Specified dose on specified days.
Study: NCT04644237
Drug: Trastuzumab deruxtecan
Normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab deruxtecan 100 mg will be provided as a sterile lyophilized powder and reconstituted with 5 mL water for injection (final concentration 20 mg/mL \[ie, 100 mg/5 mL\]). The study drug will be administered as an intravenous (IV) infusion over 30 to 90 min Q3W ± 2 days. The initial dose of study drug will be infused for 90 ± 10 min.
Study: NCT04776187
Drug: Gadodiamide
Normalized name: Gadodiamide
DrugBank: Gadodiamide (DB00225)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gadodiamide Injection(OMNISCAN™)
Study: NCT04776187
Drug: Gadoteric Acid Meglumine Salt
DrugBank: Gadoteric acid (DB09132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gadoteric Acid Meglumine Salt Injection(Jia Di Xian™)
Study: NCT06375473
Drug: Irinotecan liposome II combination therapy regimen
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Irinotecan liposome II combination therapy regimen
Study: NCT06497062
Drug: sonrotoclax
Normalized name: Sonrotoclax
DrugBank: Sonrotoclax (DB18753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally once daily, on D5-14. A 4-day dose ramp-up is required for the first induction. The dosing regimen will be determined in the Safety Run-in phase.~If a second induction is needed, dose ramp-up is not required. In the consolidation therapy phase, subjects in the group with favorable risk and MRD negative do not need to receive Sonrotoclax treatment, and subjects in the group with favorable risk and MRD positive, or with intermediate and adverse risk will receive sonrotoclax on D1-7 at the target dose determined in the safety run-in phase, dose ramp-up is not required.~In the maintenance therapy phase, subjects will receive once daily sonrotoclax on D1-14 at the target dose determined in the safety run-in phase.
Study: NCT06497062
Drug: idarubicin/daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: idarubicin: On D1-3, intravenously, 10 mg/m\^2 for subjects aged \<60 years, 6 mg/m\^2 for subjects aged ≥60 years daunorubicin: On D1-3, intravenously, 60 mg/m\^2 for subjects aged \<60 years, 40 mg/m\^2 for subjects aged ≥60 years
Study: NCT06497062
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: In induction therapy phase: intravenously, 100 mg/m\^2 on D1-7. In consolidation therapy phase: subjects with favorable-risk and MRD negative will receive cytarabine intravenously at 2 g/m\^2/q12h for those aged \<60 years, at 1g/m\^2/q12h for those ≥60 years on D1-3 or 3+7 regimen, and subjects with favorable-risk and MRD positive or intermediate or adverse-risk will receive cytarabine intravenously at 1 g/m\^2/d q12h on D1-3(in combination with sonrotoclax).
Study: NCT06497062
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 75 mg/m\^2, subcutaneously, once daily, on D1-7
Study: NCT06519656
Drug: Mazdutide
Normalized name: Mazdutide
DrugBank: Mazdutide (DB19099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the initial 4 weeks, the subjects are given Mazdutide 2mg once weekly. If well tolerated, the dosage is increased to 4mg once weekly for another 4 weeks. If still well tolerated, the dosage is further increased to 6mg once weekly and maintained for the ensuing 16 weeks.
Study: NCT06662006
Drug: nal-IRI,5-fu,LV, benmelstobart, anlotinib
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: liposomal irinotecan (nal-IRI) plus 5-fluorouracil (5-FU)/leucovorin (LV) (nal-IRI/5-FU/LV) combined with benmelstobart and anlotinib ± SBRT
Study: NCT06607666
Drug: Lanreotide autogel
DrugBank: Lanreotide (DB06791)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Identification of clinical, biochemical, molecular markers of response to low and high dose of fg-SRLs
Study: NCT05827549
Drug: Blincyto
Normalized name: Blincyto
DrugBank: Blinatumomab (DB09052)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Vincristine 1.5mg/m2, L-asparaginase 6,000 IU/m2 Idarubicin 10mg/m2 will be administered for induction therapy. Ifosfamide 1.8g/m2 Etoposide 100mg/m2 will be administered for consolidation therapy, then patients will be sorted into groups depend on their potential risk and Blinatumomab IV will be administered over 28 days. Intensification course will be administered 4 times repeated. 1. etoposide 100mg/m2 Ifosfamide 3.4g/m2 with MESNA / 2.oral 6-mercaptopurine 50mg/m2, methotrexate 25mg/m2 / 3.Ara-C 1.0g/m2, Idarubicin 5mg/m2 / 4.vincristine 2mg/m2 are the courses for repetition.
Study: NCT04659499
Drug: Nab-paclitaxel in combination with pyrotinib
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nab-paclitaxel I.V. 260mg/m2 every 3 weeks for 12 weeks plus pyrotinib oral 240mg daily for one year
Study: NCT04739618
Drug: GM-CSF
Normalized name: GM-CSF
DrugBank: Regramostim (DB05386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mL injected into each non-ablative cryosurgical freezing zone. Daily injection administered subcutaneously. 250 mcg daily injections for a total of 25 days after each treatment.
Study: NCT05840952
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Multiple doses of Midazolam
Study: NCT05840952
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multiple doses of Itraconazole
Study: NCT05840952
Drug: Carbamazepine
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multiple doses of Carbamazepine
Study: NCT06252961
Drug: Levamisole 3 days
Normalized name: Levamisole
DrugBank: Levamisole (DB00848)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levamisole for 3 days (2,5 mg/kg) then placebo for 2 days
Study: NCT06252961
Drug: Levamisole 5 days
Normalized name: Levamisole
DrugBank: Levamisole (DB00848)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levamisole for 5 days (2,5 mg/kg)
Study: NCT02887040
Drug: Atengenal
Normalized name: ATENGENAL
DrugBank: Antineoplaston A10 (DB11702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects ≥ 3 years of age with a diffuse, intrinsic brain stem glioma will receive Atengenal in combination with Astugenal (Antineoplaston therapy) and radiation
Study: NCT02887040
Drug: Astugenal
Normalized name: ASTUGENAL COMPONENT PHENYLACETIC ACID
DrugBank: Phenylacetic acid (DB09269)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects ≥ 3 years of age with a diffuse, intrinsic brain stem glioma will receive Astugenal in combination with Atengenal (Antineoplaston therapy) and radiation
Study: NCT05385887
Drug: Ciprofloxacin 500 mg
Normalized name: ciprofloxacin 500 MG
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One tablet of 500mg Ciprifloxacine, twice a day
Study: NCT05385887
Drug: Metronidazole 500 mg
Normalized name: metronidazole 500 MG
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One tablet of 500mg Metronidazole, three times a day
Study: NCT04847752
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: the dosage and duration
Study: NCT04847752
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: the dosage and duration
Study: NCT04847752
Drug: Anticoagulant
Normalized name: Anticoagulant
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: the dosage and duration
Study: NCT04821102
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: saline, 1 time injection under ultrasonic guided
Study: NCT05016661
Drug: ABP-450
Normalized name: ABPC
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ABP-450 (prabotulinumtoxinA) contains a 900 kDa botulinum toxin type-A complex produced by the bacterium Clostridium botulinum.
Study: NCT06052254
Drug: 12 cm2 - 2 Active DMTS Patches
Normalized name: lactate
DrugBank: L-Phospholactate (DB01733)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 Active DMTS patches applied to the upper back followed 7 days later by another application of 2 Active DMTS patches. Each application will be worn for 4 days (96 hours)
Study: NCT05981001
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After administration of cyclophosphamide, fludarabine will then be infused at 25 mg/m\^2 intravenous piggyback (IVPB) daily over approximately 30 minutes for five days, starting five days prior to LNL transfer.
Study: NCT05981001
Drug: Nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nab-paclitaxel will be administered at 100 mg/m\^2 IV on Days 1, 8 and 15 of each 28-day cycle until unacceptable toxic effects or disease progression or other termination criteria appeared.
Study: NCT05981001
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine will be administered at 1000 mg/m\^2 IV on Days 1 and 8 of each 21-day cycle until unacceptable toxic effects or disease progression or other termination criteria appeared.
Study: NCT05981001
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin will be administered at area under the concentration-time curve 2 (AUC 2) IV on Days 1 and 8 of each 21-day cycle until unacceptable toxic effects or disease progression or other termination criteria appeared.
Study: NCT06014606
Drug: haloperidol 2mg
Normalized name: HALOPERIDOL 2MG TAB
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral formulation
Study: NCT06014606
Drug: propranolol 40mg
Normalized name: HCTZ 25/PROPRANOLOL 40MG TAB
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral formulation
Study: NCT05767346
Drug: Aficamten (CK-3773274) (5 mg, 10 mg, 15 mg and 20 mg)
Normalized name: Aficamten
DrugBank: Aficamten (DB18490)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aficamten (CK-3773274) tablets administered orally
Study: NCT05767346
Drug: Placebo to match aficamten
DrugBank: Fica (DB03384)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for aficamten (CK-3773274) administered orally
Study: NCT05767346
Drug: Metoprolol succinate (50 mg, 100 mg, 150 mg and 200 mg)
Normalized name: metoprolol succinate 200 MG
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoprolol succinate tablets administered orally
Study: NCT05767346
Drug: Placebo to match metoprolol succinate
Normalized name: Metoprolol Succinate
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo for metoprolol succinate administered orally
Study: NCT05552261
Drug: Cenegemin in the DEFENDO Study
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cenegemin as administered in the DEFENDO Study. Long-term safety and efficacy of OXERVATE™ 0.002% (20 mcg/mL) cenegermin-bkbj ophthalmic solution administered in Stage 1 Neurotrophic Keratitis (NK) patients enrolled in the DEFENDO Study (NCT number NCT04485546).~No intervention was performed in this follow-up / extension trial.
Study: NCT04867720
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: - Oral intake, BID - After first dose 1mg(total 2mg daily), check the blood concentration of everolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 3\~8mg/mL.
Study: NCT04842630
Drug: SHR-1916
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants receive SHR-1906 alone
Study: NCT05237791
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: magnesium sulphate 50mg/kg (loading dose for 10 minutes), 15mg/kg/hr (continuous infusion)
Study: NCT05459649
Drug: Cyclosporine Oral Product
Normalized name: cyclosporine Oral Product
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A combination of cyclosporin with standard steroid in newly diagnosed ITP patients: cyclosporin was started orally 1 mg/kg/d in two divided doses for 1 week, increased to 1.5 mg/kg/d for 1week, further increased to 2.5 mg/kg/d and then continued for 24 weeks. The therapeutic serum level of cyclosporin was 75 to 150 ug/L. After 26 weeks of cyclosporin treatment, the dose for patients who achieved complete response was reduced by 25 mg/d every 2 weeks to ensure continuing the lowest dose that achieved the targeted serum level of cyclosporin and a safe platelet count; standard steroid regimen included orally prednisone for a total of 10 weeks: 1 mg per kilogram of body weight for 2 weeks followed by 40 mg daily for 2 weeks, 20 mg daily for 2 weeks, 10 mg daily for 2 weeks, 5 mg daily for 1 week and 5 mg every other day for the final week.
Study: NCT05459649
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard steroid in newly diagnosed ITP patients: orally prednisone for a total of 10 weeks: 1 mg per kilogram of body weight for 2 weeks followed by 40 mg daily for 2 weeks, 20 mg daily for 2 weeks, 10 mg daily for 2 weeks, 5 mg daily for 1 week and 5 mg every other day for the final week.
Study: NCT05718167
Drug: Anlotinib hydrochloride capsule
Normalized name: loperamide hydrochloride Oral Capsule
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib hydrochloride is a multi-target receptor tyrosine kinase inhibitor, which can target angiogenesis related kinases, such as VEGFR 1/2/3, FGFR 1/2/3 and other tumor cell proliferation related kinases like Platelet-derived growth factor receptor (PDGFR) α/β、 C-kit, RET.
Study: NCT05718167
Drug: Tislelizumab injection
Normalized name: tislelizumab Injection
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tislelizumab injection can bind to human programmed cell death 1 (PD-1), a cell membrane protein that is mainly expressed on activated T cells and inhibits T cell activation.
Study: NCT06056336
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tislelizumab 200 mg q21d up to 1 year. Nad-paclitaxel 260 mg/m2, IV., every 3 weeks, 2-3 cycles. Carboplatin area under the curve = 5, IV., every 3 weeks, 2 cycles.
Study: NCT05555797
Drug: Tazarotene Topical Gel
Normalized name: tazarotene Topical Gel
DrugBank: Tazarotene (DB00799)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tazarotene gel 0.1%(finger tip unit of the gel) will be applied once daily for weeks
Study: NCT05555797
Drug: Betamethasone Valerate
Normalized name: Betamethasone Valerate
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: .Betamethasone valerate ointment 0.1% will be applied twice daily for 12 weeks.
Study: NCT06078202
Drug: ABBV-903
Normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet; oral
Study: NCT05921695
Drug: Normal Saline infusion and Ringer lactate infusion
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The heat stroke patients will be infused with different chlorine concentrations fluid during the emergency department.
Study: NCT04137653
Drug: nab-Paclitaxel+carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Nab-P (Abraxis BioScience, LLC., Mclrose Park, IL, USA; drug license No. H20091059), 125 mg/m2, intravenous drip for 30 minutes once, on days 1 and 8, 21 days as a session for a total of 6 sessions; at the same time, carboplatin (Qilu Pharmaceutical Co., Ltd., Jinan, Shandong Province, China; drug license No. Guoji Zhunzi H20020181), AUC=2 mg•min/mL, intravenous drip for 120 minutes once, on days 1 and 8, 21 days as a session for a total of 6 sessions.
Study: NCT04137653
Drug: Paclitaxel+carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Paclitaxel (Yangtze River Pharmaceutical Co., Ltd., Taizhou, Jiangsu Province, China; drug license No. Guoyao Zhunzi H20053001), 125 mg/m2, intravenous drip for 30 minutes once, on days 1 and 8, 21 days as a session for a total of 6 sessions; at the same time, carboplatin, AUC=2 mg•min/mL, intravenous infusion for 120 minutes once, on days 1 and 8, 21 days as a session for a total of 6 sessions.
Study: NCT05312632
Drug: Safinamide Mesilate
Normalized name: Safinamide mesilate
DrugBank: Safinamide (DB06654)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Safinamide Mesilate oral tablets.
Study: NCT05475210
Drug: 177Lu-DOTA-EB-TATE
Normalized name: DOTA-TATE
DrugBank: Dotatate (DB14554)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peptide Receptor Radionucleotide Therapy ( PRRT) using 177Lu-DOTA-EB-TATE with a defined number of cycles will be administered.
Study: NCT05105750
Drug: indobufen 200 mg bid
Normalized name: indobufen
DrugBank: Indobufen (DB12545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg aspirin for at least 3 days followed by indobufen 200 mg bid
Study: NCT06188650
Drug: Anlotinib
Normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After receiving DEB-BACE treatment, the enrolled patients will rest for one week and then undergo one cycle of treatment with the combination of Anlotinib and Adebelimumab. After one course of treatment, the efficacy will be re evaluated, such as CR, and the treatment with Anlotinib and Adebelimumab will continue; For PR, SD, or PD, continue to receive DEB-BACE combined with anlotinib and adebelimumab as needed, with a maximum of 4 DEB-BACE treatments, followed by continued treatment with anlotinib and adebelimumab
Study: NCT06060132
Drug: Sodium arsenite chloride injection
Normalized name: quinine arsenite
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patient use of arsenite sodium chloride injection
Study: NCT03852992
Drug: Post-Laser Minoxidil 2%
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2ml of 20mg/ml sterile solution, applied post-laser procedure
Study: NCT03852992
Drug: At-Home Minoxidil 5%
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2ml of 50mg/ml foam q24 h for duration of study
Study: NCT03852992
Drug: Post-laser 5mg minoxidil
Normalized name: minoxidil 5 MG
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25ml of 20mg/ml sterile solution, applied post-laser procedure
Study: NCT03852992
Drug: Post-laser 10mg minoxidil
Normalized name: minoxidil 10 MG
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5ml of 20mg/ml sterile solution, applied post-laser procedure
Study: NCT03852992
Drug: Post-laser 20mg minoxidil
Normalized name: minoxidil 20 MG/ML
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1ml of 20mg/ml sterile solution, applied post-laser procedure
Study: NCT05043792
Drug: TT-00920
Normalized name: TT 173
DrugBank: TT 173 (DB17717)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TT-00920 Tablets
Study: NCT04549116
Drug: Progesterone-IBSA Injectable Solution
Normalized name: progesterone Injectable Solution
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Progesterone-IBSA 25mg, twice daily (BID) SC Injection every 12 hours
Study: NCT04549116
Drug: Progesterone Vaginal Gel with Applicator
Normalized name: progesterone Vaginal Gel
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Crinone 8%, 90 mg, QD intravaginally